¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell cycle time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • epithelioid cell nevus
    »óÇǸð¾ç¼¼Æ÷¸ð¹Ý
  • erythroid cell
    ÀûÇ÷±¸
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • ethmoidal air cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • fat-storing cell
    Áö¹æÀúÀå¼¼Æ÷
  • flagellated cell
    Æí¸ð¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • continuous cell separator
    ¿¬¼Ó¼¼Æ÷ºÐ¸®±â
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
  • crenated cell
    Åé´ÏÀûÇ÷±¸
  • crypt cell
    âÀÚ»ù¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷, ÁÖ»çÀ§¼¼Æ÷
  • cylindrical cell
    (¢¡columnar cell) ¿øÁÖ¼¼Æ÷
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹é
  • dark cell
    ¾îµÒ¼¼Æ÷
  • daughter cell
    µþ¼¼Æ÷
  • dendritic cell
    °¡Áö¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diploid cell
    µÎ¹è¼öü¼¼Æ÷
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • giant cell myocarditis
    °Å´ë¼¼Æ÷¼º ½É±Ù¿°(¡­ãýÐÉæú)
  • giant cell pneumonia
    °Å¼¼Æ÷Æó·Å.
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç.
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç.(¡­ðþåË)
  • giant cell, langhans
    ¶ûÇѽº °Å´ë¼¼Æ÷, Langhans °Å´ë¼¼Æ÷
  • giant pyramidal cell
    Å«ÇǶó¹Ô½Å°æ¿ø, °Å´ëÃßü¼¼Æ÷(¡­õÐô÷á¬øà).
  • gingiva,giant cell granuloma of
    °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • glandular cell
    »ù¼¼Æ÷, ¼±¼¼Æ÷(àÍá¬øà).
  • glandular cell
    »ù¼¼Æ÷
  • glassy cell carcinoma of cervix
    À¯¸®¾ç ¼¼Æ÷ ÀڱðæºÎ¾Ï
  • glia cell
    ¾Æ±³¼¼Æ÷, (½Å°æ)±³¼¼Æ÷.
  • gliacyte =glia cell
    ¾Æa¼¼Æ÷, (½Å°æ)a¼¼Æ÷(¡­á¬øà).
  • gliacyte =glia cell
    ¾Æ±³¼¼Æ÷, (½Å°æ)±³¼¼Æ÷(¡­á¬øà).
  • glial cell
    ¾Æa¼¼Æ÷, (½Å°æ)a¼¼Æ÷.
  • glial cell
    ¾Æ±³¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • scan time
    ÁÖ»ç½Ã°£
  • sedimentation time
    ħ°­½Ã°£( ˽ãÁÊà).
  • sensitive time
    °¨ÀÀ½Ã°£(ÊïëëãÁÊà).
  • serial thrombin time
    ¿¬¼ÓÆ®·Òºó½Ã°£(ææáÙ¡­ ãÁÊà).
  • serial thrombin time
    ¿¬¼ÓÆ®·Òºó½Ã°£(ææáÙ¡­ ãÁÊà)
  • sinoatrial conduction time
    µ¿¹æÀüµµ½Ã°£.
  • sinus node recovery time
    µ¿°áÀýȸº¹½Ã°£.
  • sleep time
    ¼ö¸é½Ã°£
  • spin lattice relaxation time (T1)
    ½ºÇÉ °ÝÀÚ ÀÌ¿Ï ½Ã°£(T1)
  • spin spin relaxation time
    ½ºÇÉ ½ºÇÉ À̿Ͻð£
  • summation time
    °¡Á߽ð£(¡­ãÁÊà).
  • survival time
    »ýÁ¸±â°£(ÊÙ˻˧).
  • survival time
    »ýÁ¸±â°£(ßæðíÑ¢Êà)
  • susception time
    °¨¼ö½Ã°£(¡­ãÁÊà).
  • synaptic time
    ½Ã³³½ºÅë°ú½Ã°£.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
VAT variable antigen type; ventricular accommodation test; ventricular activation time; vesicular amine ...
ICT icteric, icterus; indirect Coombs test; inflammation of connective tissue; insulin coma therapy; int...
MDT mast [cell] degeneration test; mean dissolution time; median detection threshold; multidisciplinary ...
RTR Recreational Therapist, Registered; red blood cell turnover rate; retention time ratio
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
MALDI-TOF MS Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry
MALDI-TOF Matrix-assisted laser desorption ionization time-of-flight
MALDI-TOF Matrix-assisted laser desorption ionization time-of-flight mass spectrometry
MPT Maximum phonation time
MCT Mean Circulation Time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • immunologically committed cell
    ¸é¿ª °æÇè ¼¼Æ÷
  • immunologically performing cell
    ¸é¿ª ¼öÇà ¼¼Æ÷
  • inflammatory cell infiltration
    ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±
    ¿°ÁõÀ» ÀÏÀ¸Å°¸é »ýü´Â ¹æ¾îÀûÀ¸·Î Ȱµ¿ÇÏ°í ¿°Áõ ¹°ÁúÀÇ Á¦°Å, ¿°ÁõÀÇ ÁøÀüÀ» ÀúÁöÇϱâ À§ÇØ ÁÖ·Î Ç÷¾×ÁßÀÇ ¹éÇ÷±¸
  • inhibitory output cell
    ¾ïÁ¦ Ãâ·Â ¼¼Æ÷
  • inhibitory substantia gelatinosa cell
    ¾ïÁ¦¼º ±³¾çÁú ¼¼Æ÷
  • interkinetic cell :

    interlabial

    ÀÔ¼ú »çÀÌÀÇ
  • intermediate cell
    Áß°£ ¼¼Æ÷
    ÁßÃþ ÆíÆò »óÇÇ Á¶Á÷ÀÇ Áß°£Ãþ, ÁÖ·Î °ú¸³ ¼¼Æ÷ÃþÀ» Â÷ÁöÇÏ´Â ¼¼Æ÷·Î¼­ ¼¼ Æ÷Áø¿¡¼­´Â Ç¥Ãþ ¼¼Æ÷º¸´Ù ¾à°£ ÀÛ¾Æ 30-50 ¸¶ÀÌÅ©·Î¹ÌÅÍÀÇ ´Ù°¢ÇüÀ̳ª À¯¿øÇüÀÇ ¿¯Àº ¼¼Æ÷ÁúÀ» Áö´Ñ ÆíÆòÇÑ ¼¼Æ÷. ÇÙÀº ¼¼Æ÷ÀÇ Á߽ɿ¡ ÀÖÀ¸¸ç, Ç¥Ãþ ¼¼Æ÷º¸´Ù´Â ¾à°£ Å©°í, ¼ÒÆ÷»óÀÇ ÇÙ³» ±¸Á¶¸¦ °üÂûÇÒ ¼ö ÀÖ´Ù.
  • interstitial cell
    °£ ¼¼Æ÷
    ôÃßµ¿¹°ÀÇ Á¤¼Ò¿¡¼­ Á¤ÀÚ Çü¼º¿¡ °ü¿©ÇÏ´Â ¼¼Æ÷ »çÀÌ¿¡ ÀÖ´Â »ý½Ä¼± ¼¼Æ÷. °£»ð ¼¼Æ÷ ¶Ç´Â ¶óÀ̵ðÈ÷
  • interstitial cell
    °£Áú ¼¼Æ÷
  • invasive squamous cell carcinoma
    ħÀÔ¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • islet cell adenoma
    Ãéµµ ¼¼Æ÷ ¼±Á¾
  • isolated T-cell deficiency
    T ¼¼Æ÷ °áÇÌ
  • juxtaglomerular cell tumor
    ¹æ»ç±¸Ã¼ ¼¼Æ÷ Á¾¾ç
  • killer T-cell
    ¼¼Æ÷ »óÇØ¼º T ¼¼Æ÷, ¼¼Æ÷»ì¼º T ¼¼Æ÷, »ìÇØ¼º T ¼¼Æ÷, ¼¼Æ÷»ìÇØ¼º T ¼¼Æ÷
  • labile cell
    ºÒ¾ÈÁ¤ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
carcinoma, acinar cell A malignant tumour arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (latin racemosus, full of clusters) refers, as does acinar (latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumour appears in all age groups and is most common in women.
(12 Dec 1998)
carcinoma, basal cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs.
(12 Dec 1998)
carcinoma, giant cell An epithelial neoplasm characterised by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid.
(12 Dec 1998)
carcinoma, islet cell A carcinoma of the islets of langerhans.
(12 Dec 1998)
carcinoma, large cell A tumour of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic.
(12 Dec 1998)
carcinoma, merkel cell A carcinoma arising from merkel cells located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of merkel cell carcinoma, occurring generally in elderly patients.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
carcinoma, renal cell Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural.
(12 Dec 1998)
carcinoma, signet ring cell A highly malignant, mucus-secreting tumour in which the mucus-secreting cells are anaplastic and appear rounded, with the nucleus displaced to one side by a globule of mucus in the cytoplasm.
(12 Dec 1998)
carcinoma, small cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterised by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. There are admixtures of small cell lung carcinoma with other types of lung cancer. Small cell carcinomas are distinguished by their distinctive biological features, response to chemotherapy and radiotherapy, and by their nearly universal tendency to develop overt or subclinical metastases, which frequently eliminates surgery in most patients.
(12 Dec 1998)
carcinoma, squamous cell A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present.
(12 Dec 1998)
carcinoma, transitional cell A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence.
(12 Dec 1998)
cardiac cell Strictly speaking any cell of or derived form the cardium of the heart, but often used loosely of heart cells.
(18 Nov 1997)
packed cell volume <haematology> Measurement of the proportion of the blood occupied by the red blood cells. Normal values are 40-54% in males, 35-47% in females.
(13 Nov 1997)
packed red blood cell <haematology> Red blood cells collected from one individual that are packed into a small volume for transfusion into a patient.
(16 Dec 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á